Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

Original reporting
Published Jun 30, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants — source image
Decision brief

The 30-second read

$VVOSBullishMed
01

Why it matters

The new insomnia dataset is positioned as a potential expansion of Vida’s use into a large underserved insomnia market, which could support higher expectations for recurring appliance sales and service revenues if validated.

02

Market read

Traders may re-rate VVOS on the prospect of label/indication expansion and a larger addressable market, but should weigh study limitations and lack of regulatory next steps.

03

What to watch

The article does not provide control/comparator data, effect durability beyond ~3.7 months average wear, adverse events details, or any FDA label expansion timeline for insomnia—key items traders may require before repricing revenue expectations.

Relevance 7/10Novelty 7/10Timing: today’s PR on newly released Vida insomnia clinical data

Background

Vivos’ Vida oral appliance is already FDA-cleared as a Class II device for TMJ disorders, migraine reduction, and nasal airway dilation; this PR adds insomnia severity outcomes from a small clinical study.

Company-level read

Ticker impact

$VVOSBullishMedium confidence
Context

Vivos reports a single-site study where its FDA-cleared Vida oral appliance improved Insomnia Severity Index in all 37 participants.

Expected impact

Near-term upside bias possible on clinical-data optimism, but magnitude likely tempered by small, single-site sample and need for validation.

Evidence & confidence

The article discloses a new clinical dataset (all participants improved; p-value ~1e-7) and frames it as a potential new revenue driver, which can move sentiment. However, it provides no revenue guidance, no multicenter confirmation, and no regulatory pathway update for insomnia, limiting conviction.

Market effects

If validated, non-pharmacologic oral appliance approaches could gain attention in insomnia/COMISA treatment pathways, potentially increasing competitive focus on device-based sleep therapeutics.

No specific regional market impact beyond Vivos’ referenced Sleep Centers of Nevada patient flow.

The company frames insomnia as a large global market and positions Vida for broader international commercial opportunity if future studies corroborate.

Counterpoint

All-participants improvement in a small, single-site study may overstate efficacy; without multicenter replication and safety/long-term durability data, the market may discount the commercial impact.

Key entities

  • Vivos Therapeutics, Inc.

    NASDAQ-listed medical device and healthcare services company marketing the Vida oral appliance.

  • Vida® oral appliance

    FDA-cleared Class II oral appliance; PR claims statistically significant insomnia severity improvement in all study participants.

  • Insomnia Severity Index (ISI)

    Validated instrument used to quantify insomnia symptoms and functional impact; study reports ~65% average ISI reduction.

Related articles

$VVOSHigh

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

$VVOSHigh

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

$BIIBMed

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

Eisai and Biogen presented 5-year data on lecanemab (LEQEMBI®) at CTAD 2026. The study showed a 36% reduction in disease progression risk, with 62% of low-tau patients improving cognitively. Continuous treatment extended time in early AD stages. Safety profile remained consistent, with ARIA-E incidence decreasing over time. Eisai leads development, with both companies co-commercializing.

$SOL-USDMed

NYSE owner deepens Solana ties, eyes validator role

Intercontinental Exchange (ICE), owner of the NYSE, is deepening ties with Solana, exploring a validator role. ICE already works with Solana in various capacities, including a digital ATS for tokenized U.S. stocks and ETFs. ICE Digital Trust supports Solana, and a Solana ETF trades on the NYSE. According to ICE, the NYSE ATS accepts Solana-minted tokens, with plans for round-the-clock settlement and instant settlement against stablecoins.